A review of the infection-associated cancers in North African countries

Infectious Agents and Cancer

Volumn 11, Issue 1, 2016, Pages

  Hussein, Wafaa Mohamed ^a   Anwar, Wagida A ^a   Attaleb, Mohammed ^b   Mazini, Loubna ^c   Försti, Asta ^d,e   Trimbitas, Roxana Delia ^c   Khyatti, Meriem ^c  

^a AIN SHAMS UNIVERSITY   (Egypt)

^b CENTRE NATIONAL DE L ENERGIE DES SCIENCES TECHNIQUES NUCLEAIRES   (Morocco)

^c Institut Pasteur du Maroc   (Morocco)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^e LUND UNIVERSITY   (Sweden)

Author keywords

Cancer; Infection; North Africa

Indexed keywords

HEPATITIS B SURFACE ANTIGEN;

BLADDER CANCER; CANCER EPIDEMIOLOGY; DISEASE ASSOCIATION; EPSTEIN BARR VIRUS INFECTION; HELICOBACTER INFECTION; HEPATITIS B; HEPATITIS C; HTLV-1 INFECTION; HUMAN; INFECTION; KAPOSI SARCOMA; LIVER CANCER; MALIGNANT NEOPLASM; NORTH AFRICAN; PRIORITY JOURNAL; REVIEW; SCHISTOSOMIASIS; STOMACH CANCER; T CELL LEUKEMIA; UTERINE CERVIX CANCER; VIRUS HEPATITIS; WART VIRUS;

EID: 85007424315     PISSN: None     EISSN: 17509378     Source Type: Journal    
DOI: 10.1186/s13027-016-0083-8     Document Type: Review

References (127)

1. de Martel C, Farley J, Franceschi S, Bray F, Forman D, Plummer M. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 2012;13(6):607-15.
2. Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 2010;19(8):1893-907.
3. Parkin D. The global health burden of infection-associated cancers in the year 2002. Int J Cancer. 2006;118(12):3030-44.
4. World Health Organization, International Agency for Rresearch on Cancer, IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Biological agents, 2012; 100 B: 39-40. [http://publications.iarc.fr/Book-And-Report-Series/Iarc-Monographs-On-The-Evaluation-Of-Carcinogenic-Risks-To-Humans/Biological-Agents-2012]. Accessed 1 Mar 2016.
5. Zanetti R, Tazi MA, Rosso S. New data tells us more about cancer incidence in North Africa. Eur J Cancer. 2010;46(3):462-6.
6. Bray F, Ren JS, Masuyer E, Ferlay J. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer. 2013;132(5):1133-45.
7. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010 [http://globocan.iarc.fr, Accessed on 25/12/2013., 2013].
8. Parkin D. The global burden of urinary bladder cancer. Scand J Urol Nephrol. 2008;42 Suppl 218:12-20.
9. Khaled H. Schistosomiasi. and Cancer in Egypt: Review. J Adv Res. 2013;4(5):461-6.
10. Steinmann P, Keiser J, Bos R, Tanner M, Utzinger J. Schistosomiasis and water resources development: Systematic review, meta-analysis, and estimates of people at risk. Lancet Infect Dis. 2006;6(7):411-25.
11. El Khoby T, Galal N, Fenwick A. The USAID/Government Egypt's Schistosomiasis Research Project (SRP). Parasitol Today. 1998;14:92-6.
12. World Bank. Egypt-National Schistosomiasis Control Project. Washington, DC: World Bank; 2008. [http://documents.worldbank.org/curated/en/2008/06/9689864/egypt-national-schistosomiasis-controlproject]. Accessed 1 Mar 2016.
13. WHO. Schistosomiasis number of people treated 2009. Wkly Epidemiol Rec. 2011;86:73-80.
14. Amarir F, El Mansouri B, Fellah H, Sebti F, Mohammed L, Handali S, et al. National serologic survey of Haematobium schistosomiasis in Morocco evidence for elimination. Am J Trop Med Hyg. 2011;84(1):15-9.
15. Barakat R, El Morshedy H, Farghaly A. Human Schistosomiasis in the Middle East and North Africa Region. In: Neglected tropical diseases - Middle East and North Africa. Mary Ann McDowell, Sima Rafati: SpringerVerlag Wien; 2014. [http://link.springer.com/book/10.1007/978-3-7091-1613-5]. Accessed 1 Mar 2016.
16. Hamdi Cherif M, Serraino D, Mahnane A, Laouamri S, Zaidi Z, Boukharouba H, et al. Time trends of cancer incidence in Setif, Algeria, 1986-2010. BMC Cancer. 2014;14:637.
17. Obtel M, Lyoussi B, Tachfouti N, Mathoulin Pelissier N, Nejjari C. Using surveillance data to understand cancer trends: an overview in Morocco. Archives of Public Health. 2015;73:45-51.
18. Missaoui N, Trabelsi A, Parkin DM, Jaidene L, Chatti D, Mokni M, et al. Trends in the incidence of cancer in the Sousse region, Tunisia, 1993-2006. Int J Cancer. 2010;127:2669-77.
19. Bodalal Z, Azzuz R, Bendardaf R. Cancers in Eastern Libya: First results from Benghazi Medical Center. World J Gastroenterol. 2014;20:6293-301.
20. Gouda I, Mokhtar N, Bilal D, El-Bolkainy T, El-Bolkainy MN. Bilharziasis and bladder cancer: a time trend analysis of 9843 patients. J Egypt Nat Cancer Inst. 2007;19(2):158-62.
21. El Sebaie I, El Bolkainy M, Hussein M. Cancer Institute registry. Med J Cairo Univ. 1973;41:175-82.
22. Lamm DL, Tori FM. Bladder Cancer. Cancer J Clin. 1996;46:93-113.
23. Felix AS, Soliman AS, Khaled H, Zaghloul MS, Banerjee M, El-Baradie M, et al. The changing pattern of bladder cancer in Egypt over the past 26 years. Cancer Causes Control. 2008;19(4):421-9.
24. Vaccarella S, Bruni L, Seoud M. Burden of human papilloma virus infections and related diseases in the extended Middle East and North Africa region. Vaccine. 2013;315:G32-44.
25. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12-9.
26. Clifford G, Franceschi S, Diaz M, Muñoz N, Villa LL. Chapter 3: HPV typedistribution in women with and without cervical neoplastic diseases. Vaccine. 2006;31(24):26-34.
27. Bosch FX, Lorincz A, Muñoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002;55(4):244-65.
28. Seoud MA, Seoud KM, Lindely S, Anis S. Human papillomavirus (HPV): Burden of the disease in cervical cancer in the extended Middle East and North Africa. A comprehensive review. J Clin Oncol 2009; 27 (suppl; abstr e16577) meeting report (2009 Asco Annual meeting).
29. Bruni L, Diaz M, Catellsague X, Ferrer E, Bosch X, de Sanjose S. Cervical Human Papillomavirus Prevalence in 5 Continents: Meta-Analysis of 1 Million Women with Normal Cytological Findings. J Infect Dis. 2010;202(12):1789-99.
30. Castellsagué X, de Sanjosé S, Aguado T, Louie K.S, Bruni L, Muñoz J, Diaz M, Irwin K, Gacic M, Beauvais O, Albero G, Ferrer E, Byrne S, Bosch F X. HPV and Cervical Cancer in the World 2007 Report. WHO/ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre) [http://www.hpvcentre.net/hpvpublications.php]. Accessed 12 Dec 2016.
31. Bruni L, Barrionuevo-Rosas L, Serrano B, Brotons M, Cosano R, Muñoz J, Bosch F, de Sanjosé S, X. C. ICO Information Centre on HPV and Cancer (HPV Information Centre). Summary Report 2013-12-16 [Data Accessed] 2013.
32. Palefsky J. HPV infection in men. Dis Markers. 2007;23(4):261-72.
33. Zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002;2(5):342-50.
34. Chin-Hong PV, Palefsky JM. Natural history and clinical management of anal human papillomavirus disease in men and women infected with human immunodeficiency virus. Clin Infect Dis. 2002;35(9):1127-34.
35. Parkin DM, et al, Cancer Incidence in Five Continents. IARC Scientific Publications No. 155, 2002. VIII.
36. Curado MP, et al, Cancer Incidence in Five Continents. IARC Scientific Publications No. 160, 2007. IX.
37. UNESCO Institute for Statistics Data Centre [online database]. Montreal, UNESCO Institute for Statistics, 2012. Available at: http://stats.uis.unesco.org [Accessed on Jan 2013]
38. Nahet A, Boublenza L, Hassaine H, Masdoua N, Prétet JL, Belglaiaa E, et al. HPV DNA genotyping: A study of anogenital, head and neck and skin cancers in a population from west Algerian. HPV detection in different cancers from an Algerian population. Bull Cancer. 2016;103:455-60.
39. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90.
40. Lu SN, Su WW, Yang SS, Chang TT, Cheng KS, Wu JC, et al. Secular trends and geographic variations of hepatitis B virus and hepatitis C virus-associated hepatocellular carcinoma in Taiwan. Int J Cancer. 2006; 119:1946-52.
41. Huang YH, Wu JC, Chau GY, Tsay SH, King KL, Sheng WY, Lui WY, Lee SD. Detection of serum hepatitis B, C, and D viral nucleic acids and its implications in hepatocellular carcinoma patients. J Gastroenterol. 1998;33:512-6.
42. Lee SD, Lee FY, Wu JC, Hwang SJ, Wang SS, Lo KJ. The prevalence of antihepatitis C virus among Chinese patients with hepatocellular carcinoma. Cancer. 1992;69:342-5.
43. Bosch FX, Ribes J, Díaz M, Cléries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology. 2004;127(5 Suppl 1):S5-16.
44. Dhanasekaran R, Limaye A, Cabrera R. Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics. Hepat Med. 2012;4:19-37.
45. Bahri O, Ezzikouri S, Alaya-Bouafif NB, Iguer F, Feydi AE, Mestiri H, et al. First multicenter study for risk factors for hepatocellular carcinoma development in North Africa. World J Hepatol. 2011;3(1):24-30.
46. Gisbert JP, García-Buey L, Pajares JM, Moreno-Otero R. Prevalence of hepatitis C virus infection in B-cell non-Hodgkin's lymphoma: systematic review and meta-analysis. Gastroenterology. 2003;125(6):1723-32.
47. Matsuo K, Kusano A, Sugumar A, Nakamura S, Tajima K, Mueller NE. Effect of hepatitis C virus infection on the risk of non-Hodgkin's lymphoma: a meta-analysis of epidemiological studies. Cancer Sci. 2004;95(9):745-52.
48. Dal Maso L, Franceschi S. Hepatitis C virus and risk of lymphoma and other lymphoid neoplasms: a meta-analysis of epidemiologic studies. Cancer Epidemiol Biomarkers Prev. 2006;15(11):2078-85.
49. Gasim IG Hepatitis B, virus in the Arab world: Where do we stand? Arab J Gastroenterol. 2013;14:35-43.
50. Khelifa F, Thibault V. Characteristics of hepatitis B viral strains in chronic carrier patients from North-East Algeria. Pathol Biol. 2009;57(1):107-13.
51. Elzouki A, Hepatitis B. C and HIV infection in Libya. Libyan J Infect Dis. 2007; 1:132-3.
52. Alashek WA, McIntyre CW, Taal MW. Hepatitis B and C infection in haemodialysis patients in Libya: prevalence, incidence and risk factors. BMC Infect Dis. 2012;12:265.
53. Salem MA, EM Elnifro EM, Alshuwen F. Molecular Analysis of Hepatitis B Virus Isolates in Libya: Predominant Circulation of Hepatitis B Virus Genotype D. J Gastroenterol Hepatol Res. 2012;1(7):119-21.
54. Ezzikouri S, Chemin I, Chafik A, Wakrim L, Nourlil J, Malki AE, et al. Genotype determination in Moroccan hepatitis B chronic carriers. Infect Genet EVol. 2008;8(3):306-12.
55. Djeriri K, Laurichesse H, Merle JL, Charof R, Abouyoub A, Fontana L, et al. Hepatitis B in Moroccan health care workers. Occup Med. 2008;58(6):419-24.
56. Sbai A, Baha W, Ougabrai H, Allalia T, Dersi N, Lazaar F, et al. Hepatitis B prevalence and risk factors in Morocco. Pathol Biol. 2012;60(5):3.
57. Zohoun A, Hadef R, Zahid H, Benkirane M. Seroprevalence of HBV and HCV in blood donors at the Blood Transfusion Center of Mohammed V Military Teaching Hospital in Rabat Morocco. Med Trop. 2011;71(5):513-4.
58. Heikel J, Sekkat S, Bouqdir F, Rich H, Takourt B, Radouani F, et al. The prevalence of sexually transmitted pathogens in patients presenting to a Casablanca STD clinic. Eur J Epidemio. 1999;15(8):711-5.
59. Benjelloun S, Bennani A, Sekkat S, Benslimane A. Les hépatites virales au Maroc. Aspects épidémiologique et moléculaire [Abstract]. Journées scientifiques de medecine. 2002;60-4:60-4.
60. Aqodad N, Lahbabi M, Elyousfi M, Mellouki I, Benajah D, Elabkari M, et al. Prevalence of VHC-Ab and HBsAg among blood donors in Guelmim in the south of Morocco. Hep Intl. 2011;5(1):96.
61. Baha W, Ennajib MM, Lazara F, Melloulc M, El Fahimec E, El Malkia A, et al. HBV genotypes prevalence, precore and basal core mutants in Morocco. Infect Genet EVol. 2012;12(6):1157-62.
62. Jemni S, Ikbel K, Kortas M, Mahjoub J, Ghachem L, Bidet JM, et al. Seropositivity to hepatitis C virus in Tunisian haemodialysis patients. Nouv Rev Fr Hemato. 1994;36(5):349-51.
63. Triki H, Said N, Ben Salah A, Arrouji A, Ben Ahmed F, Bouguerra A, et al. Seroepidemiology of hepatitis B, C and delta viruses in Tunisia. Trans R Soc Trop Med Hyg. 1997;91(1):11-4.
64. Bahri O, Cheikh I, Hajji N, Djebbi A, Maamouri N, Sadraoui A, et al. Hepatitis B genotypes, precore and core promoter mutants circulating in Tunisia. J Med Virol. 2006;78(3):353-7.
65. Meldal BH, Moula NM, Barnes IH, Boukef K, Allain JP. A novel hepatitis B virus subgenotype, D7, in Tunisian blood donors. J Gen Virol. 2009;90(Pt 7): 1622-8.
66. Sherif MM, Abou-Aita BA, Abou-Elew MH, el-Kafrawi AO. Hepatitis B virus infection in upper and lower Egypt. J Med Virol. 1985;15(2):129-35.
67. Ismail AM, Ziada HN, Sheashaa HA, Shehab El-Di AB. Decline of viral hepatitis prevalence among asymptomatic Egyptian blood donors: a glimmer of hope. Eur J Intern Med. 2009;20(5):490-3.
68. Wasfi OA, Sadek NA. Prevalence of hepatitis B surface antigen and hepatitis C virus antibodies among blood donors in Alexandria. Egypt East Mediterr Health J. 2011;17(3):238-42.
69. Said ZN, Sayed MH, Salama II, Aboel-Magd EK, Mahmoud MH, Setouhy ME, et al. Occult hepatitis B virus infection among Egyptian blood donors. World J Hepatol. 2013;5(2):64-73.
70. Lehman EM, Wilson ML. Epidemiology of hepatitis viruses among hepatocellular carcinoma cases and healthy people in Egypt: a systematic review and meta-analysis. Int J Cancer. 2009;124(3):690-7.
71. Khaled IA, Mahmoud OM, Saleh AF, Bioumie EE. Prevalence of HBV genotypes among Egyptian hepatitis patients. Mol Biol Rep. 2011;38(7):4353-7.
72. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect. 2011;17(2):107-15.
73. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45(4):529-38.
74. Guerra J, Garenne M, Mohamed MK, Fontanet A. HCV burden of infection in Egypt: results from a nationwide survey. J Viral Hepat. 2012; 19(8):560-7.
75. Roudot-Thoraval F, Deforges L, Girollet PP, Maria B, Milliez J, Pathier D, Duval J, Dhumeaux D. Prevalence of hepatitis C virus antibodies (tests ELISA 2 and RIBA 2) in a population of pregnant women in France. Gastroenterol Clin Biol. 1992;16(3):255-9. Article in French.
76. Chiaramonte M, Pupo A, Menegon T, Baldo V, Malatesta R, Trivello R. HBV and HCV infection among non-European Union immigrants in North-East Italy. Epidemiol Infect. 1998;121(1):179-83.
77. Hemminki K, Mousavi SM, Brandt A, Ji J, Sundquist J. Liver and gallbladder cancer in immigrants to Sweden. Eur J Cancer. 2010;46(5):926-31.
78. Ayed Z, Houinato D, Hocine M, Ranger-Rogez S, Denis F. Prevalence of serum markers of hepatitis B and C in blood donors and pregnant women in Algeria. Bull Soc Pathol Exot. 1995;88(5):225-8.
79. National Travel Health Network, C., Country Information, Algeria, Tunisia, Morocco, 2009.
80. Berkane S. French Luncheon comment prendre en charge les patients atteints d'hépatite C avec les médicaments disponibles en Algérie, 2009.
81. Rouabhia S, Sadelaoud M, Chaabna-Mokrane K, Toumi W, Abenavoli L. Hepatitis C virus genotypes in north eastern Algeria: A retrospective study. World J Hepatol. 2013;5(7):393-7.
82. Saleh MG, Pereira LM, Tibbs CJ, Ziu M, al-Fituri MO, Williams R, McFarlane IG. High prevalence of hepatitis C virus in the normal Libyan population. Trans R Soc Trop Med Hyg. 1994;88(3):292-4.
83. Daw MA, Elkaber MA, Drah AM, Werfalli MM, Mihat AA, Siala IM. Prevalence of hepatitis C virus antibodies among different populations of relative and attributable risk. Saudi Med J. 2002;23(11):1356-60.
84. Elasifer HA, Agnnyia YM, Al-Alagi BA, Daw MA. Epidemiological manifestations of hepatitis C virus genotypes and its association with potential risk factors among Libyan patients. Virol J. 2010;7(317):7-317.
85. Benjelloun S, Bahbouhi B, Sekkat S, Bennani A, Hda N, Benslimane A. Anti-HCV seroprevalence and risk factors of hepatitis C virus infection in Moroccan population groups. Res Virol J. 1996;147:247-55.
86. Benouda A, Boujdiya Z, Ahid S, Abouqal R, Adnaoui M. Prevalence of hepatitis C virus infection in Morocco and serological tests assessment of detection for the viremia prediction. Pathol Biol. 2009;57(5):368-72.
87. Lahlou Amine I, Zouhair S, Chegri M, L'kassmi H. Seroprevalence of anti-HCV in patients of the Military Hospital Moulay Ismail (Meknes, Morocco): Data analysis of the medical biology laboratory (2002-2005). Bull Soc Pathol Exot. 2010;103(4):255-8. [Article in French.
88. Boulaajaj K, Elomari Y, Elmaliki B, Madkouri B, Zaid D, Benchemsi N. Prevalence of hepatitis C, hepatitis B and HIV infection among haemodialysis patients in Ibn-Rochd university hospital, Casablanca] Nephrol Ther. 2005;1(5):274-84.
89. Sekkat S, Kamal N, Benali B, Fellah H, Amazian K, Bourquia A, El Kholti A, Benslimane A. Prevalence of anti-HCV antibodies and seroconversion incidence in five haemodialysis units in Morocco. Nephrol Ther. 2008;4(2): 105-10. Article in French.
90. Bahadi A, Maoujoud O, Hassani K, Akhmouch I, Doblali T, El Allam M, et al. L'hépatite C virale en hémodialyse: étude multicentrique ambispective de séroconversion et de prévalene. Néphrologie Thérapeutique. 2011;7:399-406.
91. Trimbitas RD, Serghini FZ, Lazaar F, Baha W, Foullous A, Essalhi M, et al. The "hidden" epidemic: a snapshot of Moroccan intravenous drug users. Virol J. 2014;11(43):11-43
92. Benani A, El-Turk J, Benjelloun S, Sekkat S, Nadifi S, Hda N, et al. HCV genotypes in Morocco. J Med Virol. 1997;52(4):396-8.
93. Hannachi N, Boughammoura L, Marzouk M, Tfifha M, Khlif A, Soussi S, et al. Viral infection risk in polytransfused adults: seroprevalence of seven viruses in central Tunisia. Bull Soc Pathol Exot. 2011;104(3):220-5.
94. Ben Alaya Bouafif N, Triki H, Mejri S, Bahri O, Chlif S, Bettaib J, et al. A case control study to assess risk factors for hepatitis C among a genera population in a highly endemic area of northwest Tunisia. Arch Inst Pasteur Tunis. 2007;84(1-4):21-7.
95. Mejri S, Mhalla S, Ben Yahia A, Triki H. Molecular and phylogenetic analyses of Tunisian hepatitis C virus strains subtype 1b. Ann Biol Clin. 2012;70(6): 707-16.
96. Frank C, Mohamed MK, Strickland GT, Lavanchy D, Arthur RR, Magder LS, et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet. 2000;355(9207):887-91
97. El-Zanaty F. Egypt Demographic and Health Survey 2008. Cairo, Egypt: Ministry of Health, El-Zanaty and Associates and Macro International. 2009.
98. Mohamoud YA, Mumtaz GR, Riome S, Miller D, Abu-Raddad LJ. The epidemiology of hepatitis C virus in Egypt: a systematic review and data synthesis. BMC Infect Dis. 2013;13:288-308.
99. DeWolfe Miller F, Abu-Raddad LJ. Evidence of intense ongoing endemic transmission of hepatitis C virus in Egypt. Proc Natl Acad Sci USA. 2010; 107(33):14757-62.
100. Donato F, Boffetta P, Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer. 1998;75(3):347-54.
101. El-Zayadi AR, Badran HM, Barakat EM, Attia M-D, Shawky S, Mohamed MK, et al. Hepatocellular carcinoma in Egypt: a single center study over a decade. World J Gastroenterol. 2005;11:5193-8.
102. Forman D. Helicobacter pylori and gastric cancer. Scand J Gastroenterol Suppl. 1996;220:23-6.
103. Helicobacter and Cancer Collaborative Group. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut. 2001;49(3):347-53.
104. Alaoui Boukhris S, Benajah DA, El Rhazi K, Ibrahimi SA, Nejjari C, Amarti A, et al. Prevalence and distribution of Helicobacter pylori cagA and vacA genotypes in the Moroccan population with gastric disease. Eur J Clin Microbiol Infect Dis. 2012;31(8):1775-81
105. Olama SM, El-Arman M. Helicobacter pylori in Egyptian patients with fibromyalgia syndrome. Egyptian Rheumatologist. 2013;35(3):167-73.
106. Mohammad MA, Hussein L, Coward A, Jackson SJ. Prevalence of Helicobacter pylori infection among Egyptian children: impact of social background and effect on growth. Public Health Nutr. 2008;11(3):230-6.
107. Mansour KB, Keita A, Zribi M, Masmoudi A, Zarrouk S, Labbene M, et al. Seroprevalence of Helicobacter pylori among Tunisian blood donors (outpatients), symptomatic patients and control subjects. Gastroenterol Clin Biol. 2010;34(1):75-82
108. Siai K, Ghozzi M, Ezzine H, Medjahed N, Azzouz MM. Prevalence and risk factors of Helicobacter pylori infection in Tunisian children: 1055 children in Cap-Bon (northeastern Tunisia). Gastroenterol Clin Biol. 2008;32(11):881-6.
109. Sixième colloque sur Helocobacter Pylori, L.A.d.R.s.H.-A., Palais de la Culture Moufdi Zakaria, 20 Feb 2011.
110. Mégraud F, Brassens-Rabbé MP, Denis F, Belbouri A, Hoa DQ. Seroepidemiology of Campylobacter pylori infection in various populations. J Clin Microbiol. 1989;27(8):1870-3.
111. Zhou X, Cui J, Macias V, Kajdacsy-Balla AA, Ye H, Wang J, Rao PN. The progress on genetic analysis of nasopharyngeal carcinoma. Comp Funct Genomics. 2007;57513(10):57513.
112. Chang ET, Adami HO. The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev. 2006;15(10):1765-77.
113. IARC, Lyon, France: World Health Organization. Epstein-Barr Virus and Kaposi's Sarcoma Herpesvirus/Human Herpesvirus 8. 1997.
114. Rickinson AB, Kieff E. Epstein-Barr Virus. Virology. 2007;5:2655-700.
115. Belbaraka R, Lalya I, Boulaamane L, Tazi M, Benjaafar N, Errihani H. Dietary risk factors of undifferenced nasopharyngeal carcinoma: a case-control study. Tunis Med. 2013;91(6):406-9.
116. Feng BJ, Jalbout M, Ayoub WB, Khyatti M, Dahmoul S, Ayad M, et al. Dietary risk factors for nasopharyngeal carcinoma in Maghrebian countries. Int J Cancer. 2007;121(7):1550-5.
117. El Kassimi B, Benchemsi N, Mikou O, El Ouazzani T, Lakhdar H. Maladie de Kaposi et anticorps anti-herpès virus-8 au Maroc. Med Mal Infect. 2003;33(4): 226-8.
118. Errihani H, Berrada N, Raissouni S, Rais F, Mrabti H, Rais G. Classic Kaposi's sarcoma in Morocco: clinico-epidemiological study at the National Institute of Oncology. BMC Dermatol. 2011;11:15-20.
119. Sodqi M, Marih L, Lahsen AO, Bensghir R, Chakib A, Himmich H, et al. Causes of death among 91 HIV-infected adults in the era of potent antiretroviral therapy. Presse Med. 2012;41(7-8):e386-90.
120. Hannachi N, Ben Fredj N, Samoud S, Ferjani A, Khlif A, Boughammoura L, et al. Seroprevalence and risk factors of human herpes virus 8 infection in Central-East Tunisia. Pathol Biol. 2012;60(5):282-6.
121. Lahlaoui H, Niija H, Ben Moussa M. Seroprevalence of human herpesvirus 8 in kidney transplant recipients in a single-center study from Tunisia. Iran J Kidney Dis. 2012;6(1):14-6.
122. Harzallah K, Abderrahim E, Chareffedine K, Yeich S, Belhadj R, Skhiri H, et al. Cancers after renal transplantation: multicenter experience. Saudi J Kidney Dis Transpl. 2008;19(5):825-30.
123. Mseddi M, Marrekchi S, Abdelmaksoud W, Bouassida S, Meziou TJ, Boudaya S, et al. Epidemio-clinical profile of skin cancer in southern Tunisia. Tunis Med. 2007;85(6):505-8.
124. Dhrif AS, Kilani B, Ammari L, Kanoun F, Tiouri H, Ben CT. AIDS-associated Kaposi's sarcoma: 22 cases. Tunis Med. 2007;85(6):494-9.
125. Andreoni M, Sarmati L, Nicastri E, El Sawaf G, El Zalabani M, Uccella I, et al. Primary human herpesvirus 8 infection in immunocompetent children. JAMA. 2002;287(10):1295-300.
126. Blattner W, Takatsuki K, Gallo R. Human T-cell leukemia lymphoma virus and adult T-cell leukemia. JAMA. 1983;250:1074-80.
127. De-The G, Gessain A, Gazzolo L. Comparative seroepidemiology of HTLV-I and HTLV-II in the French West Indies and some African countries. Cancer Res. 1985;45(9):S4633-6.